Novel Anti-Alzheimer Therapeutics Discovery and Development
Alzheimer Disease (AD)– Research and Development
The Novel anti-AD antibody-based Drugs Development
The Novel anti-AD antibody-based Drugs Development
Alzheimer disease (AD) is uniquely characterized amyloid dysregulation (Amyloid Aggregate > Clear). The emerging paradigm: Target Aβ Oligomers
The Novel anti-AD antibody-based Drugs Development
The Novel anti-AD antibody-based Drugs Development
The Novel anti-AD antibody-based Drugs Development
Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases
Developing Novel Anti-Aβ, tau and α-Syn
The Novel anti-AD antibody-based Drugs Development
The innovative anti- Aβ therapeutic Bispecific antibody candidates development
Developing anti Aβ, Tau and α-Syn bispecific and multi- therapeutic antibody and Fc fusion proteins candidates
The innovative anti- Aβ therapeutic Bispecific antibody candidates development
The innovative anti- Aβ therapeutic Bispecific antibody candidates development
The innovative anti- Aβ therapeutic Bispecific antibody candidates development
The several Anti- Aβ therapeutic Bispecific antibody candidates have been selected
Development of multi- targets therapeutic candidates for AD
The innovative anti- Aβ therapeutic Bispecific antibody candidates development
Development of enhancing the BBB infiltration therapeutic candidates
The multi- targets therapeutic candidates for AD have been generated
Development of enhancing the BBB infiltration therapeutic candidates
The innovative anti- Aβ therapeutic Bispecific antibody candidates development
Development of enhancing the BBB infiltration therapeutic candidates
The candidates of enhancing the BBB infiltration therapeutics for AD have been selected
